Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol

Flavanol-rich cocoa and dark chocolate for blood pressure

A Cochrane review of 35 trials in 1,804 mainly healthy people found flavanol-rich cocoa lowered systolic pressure about 1.8 mmHg over 2 to 18 weeks.

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

Cocoa and dark chocolate contain plant compounds called flavanols. In 35 short trials, mostly in healthy people, cocoa rich in flavanols lowered blood pressure by less than 2 points on average. Most trials used special high-flavanol products, not ordinary chocolate bars. The trials lasted from two weeks to about four months. None of them measured heart attacks or strokes.

The letter, taken apart
What was measured
Blood pressure after 2 to 18 weeks.
How big
Systolic pressure 1.76 mmHg lower.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 28439881.
Who it applies to
Mainly healthy adults over a few weeks.
Safety
Chocolate products add sugar and calories; the trials used flavanol-standardized products.
The record in one view
Compared with
Flavanol-free or low-flavanol cocoa products.
Certainty
Grade C, resting on: Cochrane meta-analysis A study that pools the numbers from several trials into one combined estimate. of 35 short randomized trials.
What would change this grade
Could rise to B with: Randomized trial of cocoa flavanols. Who: Adults with hypertension. Measured: 24-hour blood pressure. Length: At least 6 months.
Cost
No price recorded yet.
Sources
3 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
CSurrogate biomarker Grade C

A Cochrane review of 35 trials in 1,804 mainly healthy people found flavanol-rich cocoa lowered systolic pressure about 1.8 mmHg over 2 to 18 weeks. The effect is small, short-term and varied unexplained between trials, so the letter is C. Cardiovascular events from cocoa flavanol extract are on a separate record.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C on blood pressure. Pooled across 35 trials, flavanol-rich cocoa lowered systolic pressure by about 1.8 mmHg (Ried et al., 2017; PMID 28439881).

WHY NOT Bthe pooled effect is about 2 to 3 mmHg (an updated 2026 meta-analysis of 25 studies found 2.7 mmHg; Sakuda et al., PMID 42679502), and in COSMOS, cocoa extract taken for a median 3.4 years did not lower the rate of new hypertension (Hamaya et al., 2025; PMID 40832703). The trials pooled were 2 to 18 weeks long with unexplained variation between them, the same standard applied to beetroot and flaxseed.

WHAT THIS GRADE DOES NOT COVERcardiovascular events, covered on the cocoa flavanol extract record, and sugar-sweetened chocolate products. It also does not cover people with treated hypertension over months or years, which the short trials did not study.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: meta-analysis

Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Blood pressure (surrogate)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of cocoa flavanols
PopulationAdults with hypertension
Endpoint24-hour blood pressure
DurationAt least 6 months

A positive trial of this shape, supported by further trials, would move this entry to B.

Why the current trials fall short

A longer trial in hypertension with a larger effect would be needed.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Cocoa among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Cocoa on ClinicalTrials.gov

Dose, form and timing

What to track

Blood pressure.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 447 · November 2026 · First graded.
Grade history
No. 447 · November 2026 · First graded
Flavanol-rich cocoa and dark chocolate for blood pressure enters the food section: Grade C

New record in the food section. A Cochrane review of 35 trials in 1,804 mainly healthy people found flavanol-rich cocoa lowered systolic pressure about 1.8 mmHg over 2 to 18 weeks. The effect is small, short-term and varied unexplained between trials, so the letter is C. Cardiovascular events from cocoa flavanol extract are on a separate record.PMID 28439881

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullThree papers, each linked to its PubMed record.
The evidence

Ried et al. (Cochrane Database Syst Rev, 2017; PMID 28439881): 35 randomized trials, 40 comparisons, 1,804 mainly healthy participants, 30 to 1,218 mg flavanols a day for 2 to 18 weeks; systolic pressure 1.76 mmHg lower (95% CI 0.43 to 3.09) than flavanol-free or low-flavanol control. Sakuda et al. (J Nutr Health Aging, 2026; PMID 42679502): updated meta-analysis of 25 studies, 1,167 participants; systolic pressure 2.7 mmHg lower. Hamaya et al. (Hypertension, 2025; PMID 40832703): COSMOS, cocoa extract against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. in older adults for a median 3.4 years; no effect on new hypertension (hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 0.96, 95% CI 0.88 to 1.05).

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 20 records screened, 1 eligible for the graded claim.
Query: (cocoa[tiab] OR chocolate[tiab] OR flavanol*[tiab]) AND "blood pressure"[tiab] AND (randomized controlled trial[pt] OR meta-analysis[pt])
The 20 most recent of 102 records were screened by title. The 2026 updated meta-analysis (PMID 42679502) and the COSMOS hypertension trial (PMID 40832703) were read and are on the record; neither raises the letter.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Hamaya et al., 2025, Hypertension (PMID 40832703): PubMed lists funding from US National Institutes of Health (National Center for Advancing Translational Sciences); US National Institutes of Health (National Institute on Aging); US National Institutes of Health (National Heart, Lung, and Blood Institute); US National Institutes of Health (National Eye Institute). The PubMed record carries a competing-interest statement.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026